Cite
APA Citation
Nilsson, F. O. L., Gal, P., Houisse, I., Ivanova, J. I., & Asanin, S. T. (2021). the cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden. Journal of medical economics, 24, 447–457. http://access.bl.uk/ark:/81055/vdc_100127437290.0x000037